论文部分内容阅读
目的:检测初诊多发性骨髓瘤(MM)患者血清白细胞介素-16(IL-16)的表达水平,探讨IL-16在MM发生发展中的作用及临床意义。方法:采用ELISA法检测MM患者治疗前后血清IL-16和IL-6的水平。结果:MM初诊未治疗组血清IL-16、IL-6水平明显高于对照组(P<0.05),且随临床分期增加而依次增高,差异有统计学意义(P<0.05),血清IL-16水平与IL-6水平呈正相关(r=0.784,P<0.01)。与治疗前相比,治疗有效组(CR+PR)血清IL-16、IL-6水平明显下降(P<0.01,t=21.036,19.367),而治疗无效组(无效或死亡)差异无统计学意义(P>0.05)。结论:MM患者血清IL-16高表达,与MM的发生、发展有关,有可能成为潜在的治疗靶点。
Objective: To detect the expression of serum interleukin-16 (IL-16) in patients with newly diagnosed multiple myeloma (MM) and to explore the role and clinical significance of IL-16 in the development of MM. Methods: Serum levels of IL-16 and IL-6 were measured by ELISA before and after treatment in MM patients. Results: The levels of IL-16 and IL-6 in untreated MM group were significantly higher than those in control group (P <0.05), and increased with the increase of clinical stage, the difference was statistically significant (P <0.05) 16 level was positively correlated with IL-6 level (r = 0.784, P <0.01). Compared with those before treatment, the levels of IL-16 and IL-6 in CR + PR group were significantly decreased (P <0.01, t = 21.036 and 19.367), but there was no significant difference between the treatment-ineffective group (ineffective or death) Significance (P> 0.05). Conclusion: The high expression of serum IL-16 in patients with MM is related to the occurrence and development of MM, which may become a potential therapeutic target.